[Clinical study of @entity3398 in chronic XXXX : evaluation in poorly responding cases to other antibiotics (author's transl)].

@entity1 @entity5443 @entity1729 @entity3398
The therapeutic efficacy of @entity3398 ( @entity5443 ) in chronic @entity1729 was evaluated in @entity1 who poorly responded to other antibiotics. To 20 @entity1 , @entity5443 was administered 2 g b.i.d. intravenously by drip infusion. Clinical efficacy was judged based on the criteria by score. 1. Bacterial elimination rate with @entity5443 was 73.7%. 2. A clinical cure rate was 80.0% was obtained by doctors in charge. 3. According to the score assessment, the overall clinical effectiveness rate was 60.0%, clinical symptom cure rate was 85.0% and improvement rate of X-ray findings was 55.0%. 4. Usefulness rate which was assessed by clinical effect and side effect was 70.0%. 5. No side effects and abnormal laboratory findings were observed in this study. We used the new antibiotic @entity5443 in @entity1 with chronic @entity1729 who responded poorly to other antibiotics and obtained satisfactory results. Especially @entity5443 indicated more effective possibility in cases from whom Gram-negative bacilli was isolated.
